Obesity Paradox Not Observed among Patients with Angiographically Proved Coronary Artery Disease in Southern China
Hua Chai,Wei Liu,Chen Zhang,Yong Peng,Xu Yang,Mao Chen,Dejia Huang
DOI: https://doi.org/10.1016/j.jjcc.2014.04.014
IF: 2.974
2014-01-01
Journal of Cardiology
Abstract:We read Dr Kaneko and colleagues’ article [[1]Kaneko H. Yajima J. Oikawa Y. Tanaka S. Fukamachi D. Suzuki S. Sagara K. Otsuka T. Matsuno S. Funada R. Kano H. Uejima T. Koike A. Nagashima K. Kirigaya H. et al.Obesity paradox in Japanese patients after percutaneous coronary intervention: an observation cohort study.J Cardiol. 2013; 62: 18-24Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar] which revealed the “obesity paradox” among Japanese patients with coronary artery disease (CAD) after percutaneous coronary intervention with great interest. We also noticed Dr Lin and colleagues’ comments [[2]Lin G.-M. Li Y.-H. Lin C.-L. Wang J.-H. Han C.-L. The obesity–mortality paradox phenomenon among Asian patients following percutaneous coronary artery intervention.J Cardiol. 2013; 62: 379Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar] about this phenomenon. According to our current knowledge, obesity paradox tended to appear when the follow-up period was relatively short, more bare-metal stents were used, or major adverse cardiovascular events (MACEs) rather than all-cause death was set as the research endpoint. However, did racial differences matter in obesity paradox phenomenon? Although this phenomenon is seen worldwide, it seemed to be more frequently reported in eastern Asian countries such as Japan [[1]Kaneko H. Yajima J. Oikawa Y. Tanaka S. Fukamachi D. Suzuki S. Sagara K. Otsuka T. Matsuno S. Funada R. Kano H. Uejima T. Koike A. Nagashima K. Kirigaya H. et al.Obesity paradox in Japanese patients after percutaneous coronary intervention: an observation cohort study.J Cardiol. 2013; 62: 18-24Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar] and Korea [[3]Park D.-W. Kim Y.-H. Yun S.-C. Ahn J.-M. Lee J.-Y. Kim W.-J. Kang S.J. Lee S.W. Lee C.W. Park S.W. Park S.J. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention.Circ Cardiovasc Interv. 2013; 6: 146-153Crossref PubMed Scopus (37) Google Scholar]. But in China, another eastern Asian country, this phenomenon was not observed in two cohorts from a northern Chinese population [4Wang Z.J. Zhou Y.J. Liu Y.Y. Yu M. Shi D.M. Zhao Y.X. Guo Y.H. Cheng W.J. Nie B. Ge H.L. Jia D.A. Yang S.W. Yan Z.X. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.Heart. 2009; 95: 1587-1592Crossref PubMed Scopus (30) Google Scholar, 5Li Y. Wu C. Sun Y. Jiang D. Zhang B. Ren L. Gao Y. Yu H. Yang G. Guan Q. Tian W. Zhang H. Guo L. Qi G. Obesity paradox: clinical benefits not observed in obese patients with ST-segment elevation myocardial infarction: a multicenter, prospective, cohort study of the northern region of China.Int J Cardiol. 2013; 168: 2949-2950Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar]. Here come the questions: How would it be in southern China where the environment, climate, food, and other lifestyles are distinct from the northern region? Should we adopt more active body weight control strategies for overweight Chinese CAD patients? To answer these questions, we conducted a prospective cohort study among 3686 patients who were angiographically diagnosed as having CAD and survived to discharge between July 2008 and September 2012 in our hospital, a 4950-bed teaching hospital affiliated to Sichuan University. Baseline information including age, gender, height, body weight, medical history, cigarette smoking history, and alcohol consumption history were collected in the catheter laboratory before percutaneous coronary angiography procedures. All patients were followed up between March 2011 and February 2014 by telephone interviews and medical record reviews with a median observational period of 27.0 months. Medications and endpoint events including all-cause deaths, nonfatal myocardial infarctions, nonfatal strokes, and coronary revascularizations were recorded during follow-up. MACE was defined as the composite endpoint of this study that included at least one event among all-cause death, nonfatal myocardial infarction, nonfatal stroke, and coronary revascularization. A total of 3231 patients completed the follow-up. The average age of the study population was 64.4 ± 10.7 years. There were 2573 male patients (79.6%), 1800 patients (55.7%) with prior history of hypertension (HTN), 635 patients (19.7%) with prior history of hypercholesterolemia (HyChol), 719 patients (22.3%) with prior history of type 2 diabetes mellitus (T2DM), and 1100 patients (34.0%) with prior history of myocardial infarction. There were 1005 patients (31.1%) who were current smokers, and 400 (12.4%) patients currently drinking alcohol. Body mass index (BMI) was calculated by dividing body weight (in kilograms) by square of the height (in meters). The patients were divided into four groups according to baseline BMI. There were 233 patients (7.2%) in the underweight group (BMI < 20 kg/m2), 1806 patients (55.9%) in the normal weight group (20 kg/m2 ≤ BMI < 25 kg/m2), 1104 patients (34.2%) in the overweight group (25 kg/m2 ≤ BMI < 30 kg/m2), and 88 patients (2.7%) in the obese group (BMI ≥ 30 kg/m2). At follow-up, there were 2499 patients (77.3%) taking antiplatelet medications, 1835 patients (56.8%) taking statins, 1551 patients (48.0%) taking beta receptor blockers (βRBs), and 911 patients (28.2%) taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). A total of 531 MACEs (16.4%) occurred during the observational period including 214 all-cause deaths, 121 nonfatal myocardial infarctions, 68 nonfatal strokes, and 193 coronary revascularizations. Among the four groups of patients, the percentage of male gender (p = 0.011), prior history of HTN (p < 0.001), prior history of HyChol (p < 0.001), taking antiplatelet medications (p = 0.033), taking βRBs (p = 0.018), and taking ACEI/ARBs (p = 0.003) increased as BMI increased, whereas age decreased (p < 0.001) as BMI increased. The percentage of current smoking was lower in the normal body weight group than in the other three groups (p = 0.038). There were no significant differences in percentage of prior history of T2DM (p = 0.075), prior history of myocardial infarction (p = 0.090), current alcohol drinking (p = 0.371), and taking statins (p = 0.231) between the four groups. The incidence of MACE was 25.3% in the underweight group, 16.1% in the normal weight group, 15.7% in the overweight group, and 10.2% in the obese group (p = 0.001). According to the results above, lower incidence of MACE in the overweight and obese groups might be partly explained by younger ages and better medication adherence. In order to determine the “genuine” risk and protective factors of MACE, univariate and multivariate analyses were conducted. Univariate analyses were performed for each variable, including age (p < 0.001), gender (p = 0.626), BMI (p = 0.001), prior history of HTN (p = 0.082), prior history of HyChol (p = 0.871), prior history of T2DM (p = 0.001), prior history of myocardial infarction (p = 0.085), current smoking (p = 0.188), current alcohol drinking (p = 0.023), antiplatelet therapy (p < 0.001), taking statins (p < 0.001), taking βRBs (p < 0.001), and taking ACEI/ARBs (p = 0.001). All variables with a p value of <0.100 were included in multivariate analysis which was performed by using a multiple forward stepwise logistic regression model. Among the variables which finally entered the logistic regression equation, age [odds ratio (OR): 1.019, 95% confidence interval (CI): 1.009–1.029], underweight (OR: 1.650, 95% CI: 1.180–2.308), prior history of T2DM (OR: 1.376, 95% CI: 1.104–1.717), and prior history of myocardial infarction (OR: 1.241, 95% CI: 1.015–1.518) were risk factors, while antiplatelet therapy (OR: 0.279, 95% CI: 0.228–0.340) was a protective factor. When compared to normal body weight, factors of overweight and obesity did not enter the logistic regression equation. We came to a conclusion that according to this study “obesity paradox” phenomenon was not observed among the patients with angiographically proved CAD in southern China. Although underweight was a risk factor of MACE, overweight and obesity did not benefit the prognosis of these patients. This conclusion was consistent with the two previous studies in northern China and implied that racial differences might play a role in “obesity paradox” phenomenon. As a result, active strategies for body weight control should still be recommended in overweight Chinese CAD patients.